183 related articles for article (PubMed ID: 35071824)
21. Mutational Frequencies of SARS-CoV-2 Genome during the Beginning Months of the Outbreak in USA.
Kaushal N; Gupta Y; Goyal M; Khaiboullina SF; Baranwal M; Verma SC
Pathogens; 2020 Jul; 9(7):. PubMed ID: 32668692
[TBL] [Abstract][Full Text] [Related]
22. Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and Other Coronaviruses: A Genome-wide Comparative Annotation and Analysis.
Tarique M; Ahmad S; Malik A; Ahmad I; Saeed M; Almatroudi A; Qadah T; Murad MA; Mashraqi M; Alam Q; Al-Saleh Y
Mol Cell Biochem; 2021 May; 476(5):2203-2217. PubMed ID: 33564990
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species.
Moustaqil M; Ollivier E; Chiu HP; Van Tol S; Rudolffi-Soto P; Stevens C; Bhumkar A; Hunter DJB; Freiberg AN; Jacques D; Lee B; Sierecki E; Gambin Y
Emerg Microbes Infect; 2021 Dec; 10(1):178-195. PubMed ID: 33372854
[TBL] [Abstract][Full Text] [Related]
24. Drugs swapping in coronavirus strains: a structural biology view.
Gurjar V; Iqra Kamil S; Chandra A; Qamar I; Singh N
J Biomol Struct Dyn; 2023; 41(22):13488-13495. PubMed ID: 36744537
[TBL] [Abstract][Full Text] [Related]
25. GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.
Rudd CE
Front Immunol; 2020; 11():1638. PubMed ID: 32695123
[TBL] [Abstract][Full Text] [Related]
26. The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor of RNA Silencing in Mammalian Cells.
Cui L; Wang H; Ji Y; Yang J; Xu S; Huang X; Wang Z; Qin L; Tien P; Zhou X; Guo D; Chen Y
J Virol; 2015 Sep; 89(17):9029-43. PubMed ID: 26085159
[TBL] [Abstract][Full Text] [Related]
27. Structural Similarity of SARS-CoV2 M
Bafna K; Krug RM; Montelione GT
ChemRxiv; 2020 Apr; ():. PubMed ID: 32511291
[TBL] [Abstract][Full Text] [Related]
28. Designing an effective therapeutic siRNA to silence RdRp gene of SARS-CoV-2.
Shawan MMAK; Sharma AR; Bhattacharya M; Mallik B; Akhter F; Shakil MS; Hossain MM; Banik S; Lee SS; Hasan MA; Chakraborty C
Infect Genet Evol; 2021 Sep; 93():104951. PubMed ID: 34089909
[TBL] [Abstract][Full Text] [Related]
29. Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.
Sohrab SS; El-Kafrawy SA; Mirza Z; Kamal MA; Azhar EI
Curr Pharm Des; 2018; 24(1):62-77. PubMed ID: 29119921
[TBL] [Abstract][Full Text] [Related]
30. In silico prediction and experimental evaluation of potential siRNAs against SARS-CoV-2 inhibition in Vero E6 cells.
Sartaj Sohrab S; Aly El-Kafrawy S; Ibraheem Azhar E
J King Saud Univ Sci; 2022 Jun; 34(4):102049. PubMed ID: 35493709
[TBL] [Abstract][Full Text] [Related]
31. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.
Kilianski A; Mielech AM; Deng X; Baker SC
J Virol; 2013 Nov; 87(21):11955-62. PubMed ID: 23986593
[TBL] [Abstract][Full Text] [Related]
32. Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources.
Razali R; Asis H; Budiman C
Microorganisms; 2021 Nov; 9(12):. PubMed ID: 34946083
[TBL] [Abstract][Full Text] [Related]
33. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease.
Bosken YK; Cholko T; Lou YC; Wu KP; Chang CA
Front Mol Biosci; 2020; 7():174. PubMed ID: 32850963
[TBL] [Abstract][Full Text] [Related]
34. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
35. Genomic analysis and comparative multiple sequences of SARS-CoV2.
Chang TJ; Yang DM; Wang ML; Liang KH; Tsai PH; Chiou SH; Lin TH; Wang CT
J Chin Med Assoc; 2020 Jun; 83(6):537-543. PubMed ID: 32349035
[TBL] [Abstract][Full Text] [Related]
36. Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus.
Báez-Santos YM; Mielech AM; Deng X; Baker S; Mesecar AD
J Virol; 2014 Nov; 88(21):12511-27. PubMed ID: 25142582
[TBL] [Abstract][Full Text] [Related]
37. All hands on deck: SARS-CoV-2 proteins that block early anti-viral interferon responses.
Setaro AC; Gaglia MM
Curr Res Virol Sci; 2021; 2():100015. PubMed ID: 34786565
[TBL] [Abstract][Full Text] [Related]
38. Comparative Genomics and Integrated Network Approach Unveiled Undirected Phylogeny Patterns, Co-mutational Hot Spots, Functional Cross Talk, and Regulatory Interactions in SARS-CoV-2.
Gupta V; Haider S; Verma M; Singhvi N; Ponnusamy K; Malik MZ; Verma H; Kumar R; Sood U; Hira P; Satija S; Singh Y; Lal R
mSystems; 2021 Feb; 6(1):. PubMed ID: 33622851
[TBL] [Abstract][Full Text] [Related]
39. Design of Potential RNAi (miRNA and siRNA) Molecules for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Gene Silencing by Computational Method.
Nur SM; Hasan MA; Amin MA; Hossain M; Sharmin T
Interdiscip Sci; 2015 Sep; 7(3):257-65. PubMed ID: 26223545
[TBL] [Abstract][Full Text] [Related]
40. Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach.
Murugan NA; Kumar S; Jeyakanthan J; Srivastava V
Sci Rep; 2020 Nov; 10(1):19125. PubMed ID: 33154404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
